Arun B. Jesudian, MD: So, Steve, I’ll give you this question then. If we’re not checking ammonia levels, how are you going to classify the severity of someone’s hepatic encephalopathy? And specifically, if you wouldn’t mind talking about the West Haven criteria, which are perhaps the most widely utilized.
Steven L. Flamm, MD: When you’re talking about overt encephalopathy, which is encephalopathy that’s clinically diagnosed, it’s what health-care providers, and patients, and their families care the most about. This is diagnosed clinically. You know a patient has cirrhosis and portal hypertension, and they have the signs and symptoms compatible with HE and you treat it, not with ammonia levels. It’s a clinical diagnosis.
Now, within the context of overt encephalopathy, when you make that diagnosis on a patient, as I mentioned earlier, there is a very wide spectrum of presentation. And there are 4 stages, not counting stage 0, which means you don’t have encephalopathy. There are stages I through IV of encephalopathy. Stage I is under the rubric of minimal, or I should say it’s under the rubric of covert encephalopathy. This group of patients have very subtle symptoms, symptoms that are so nonspecific that it’s hard to even necessarily attribute them to encephalopathy, like fatigue, like changes maybe in work performance, sleep/wake reversal, very early changes that aren’t really definitive mentation changes.
Once you start to get to II, III, and IV, this is where we call it overt encephalopathy rather than covert encephalopathy. Stage II is probably the most common. That’s where patients start to have personality changes, inappropriate behavior, maybe slurred speech. This is where patients first start to develop asterixis, the flapping of the hands, stage II. Frequently, but not always, these patients are hospitalized. Stage III, which is less common, is much more serious even. And this is where patients have overtly bizarre behavior. They may be stuporous. They’re not in a coma, but they’re really not responding to questions at all appropriately. Stage III, these people are all admitted often to the ICU [intensive care unit]. And then stage IV is coma, and the coma may be responsive to noxious stimuli or unresponsive to noxious stimuli. Either way, these patients are almost always hospitalized in an intensive care unit.
So the actual grade or the class from these criteria is not critical in private practice, I would say. We use it in research. It’s important, but for the practitioner to grade it, it’s not critical. Certainly, when you have a patient with HE you should document in the chart a little bit what their signs and symptoms are, so that when you see the patient and when others see the patient in following days, they can get an idea of how the patient is doing. Are they doing worse or are they doing better? Not just [that] they have HE. What are the issues, because I think it helps you know if the patient is responding to therapy.
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More